Member News

Cloud computing support accelerates COVID-19 vaccine improvements

University of British Columbia
By University of British Columbia
May 15, 2021

For the last 12 months, University of British Columbia biochemistry and molecular biology professor Leonard Foster and his team have been studying how SARS-CoV-2 — the virus responsible for COVID-19 — attacks the human body, in hopes of developing a more targeted vaccine with fewer side effects.

Foster is confident that this technology will accelerate the development of second-generation vaccine candidates.

Foster-Leonard-445x426.jpg
University of British Columbia
 Leonard Foster and his team at UBC have been studying how SARS-CoV-2 —
 the virus responsible for COVID-19 — attacks the human body, in hopes of
developing a more targeted vaccine with fewer side effects.

"There are many different approaches to developing a vaccine," Foster said. "The current COVID-19 vaccines use a brute-force approach that throws everything we know about the virus at our immune system and hopes that there is something in there that will cause an immune response. But by studying how the virus actually causes disease, we can apply a more targeted approach and develop a more effective vaccine with minimal side effects."

Foster has been studying how pathogens such as bacteria and viruses cause disease in host organisms for more than a decade. He specializes in a technique called mass spectrometry that is used to identify and analyze specific proteins in pathogens that allow them to cause disease. Once those proteins are identified, the researchers can use the information to develop a targeted vaccine.

Before the pandemic, Foster was known for his work applying mass spectrometry to understand how pathogens affect honey bees in order to guide selective breeding for disease-resistant behaviours in bees. Now he's applying the same technology to better understand the novel coronavirus.

"By studying how the virus actually causes disease, we can apply a more targeted approach and develop a more effective vaccine with minimal side effects."
 Leonard Foster

"The types of experiments we do generate huge datasets that need to be analyzed and interpreted computationally," Foster said. "If someone was to use a pen, paper and a calculator, it might take them beyond the life of the universe to come up with results. With our existing resources, we may be able to come up with something in five to 10 years. But thanks to our collaboration with Microsoft, we have accessed cloud computing power that results in us being able to see results within months."

The research is supported by a Mitacs project, and leverages Microsoft's donation of its Azure cloud platform credits to the university through UBC Advanced Research Computing. This enabled Foster's team to pivot quickly to analyze huge amounts of new and existing data using an application that runs on the powerful cloud platform.

"The cloud computing resources have impacted our research instrumentally and significantly sped up our vaccine development," Foster said. "We've been able to do some experiments that were not conceivable with any of the other resources that we had."

Foster's work is especially important as scientists don't yet know how long immunity against COVID-19 will last with the current available vaccines due to a lack of data.

"By understanding the mechanism of this virus, we'll be able to develop the next generation of prevention and treatment methods, as well as laying the groundwork for the basic scientific knowledge in preparation for the next pandemic-causing virus," he said.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
University of British Columbia
University of British Columbia

This article was written by a staff member in the University of British Columbia Faculty of Medicine communications office.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Mutant RNA exosome protein linked to neurodevelopmental defects
Journal News

Mutant RNA exosome protein linked to neurodevelopmental defects

Feb. 4, 2025

Researchers at Emory University find that a missense mutation impairs RNA exosome assembly and translation and causes neurological disease.

Study sheds light on treatment for rare genetic disorder
News

Study sheds light on treatment for rare genetic disorder

Feb. 2, 2025

Aaron Hoskins’ lab partnered with a drug company to understand how RNA-targeting drugs work on spinal muscular atrophy, a disorder resulting from errors in production of a protein related to muscle movement.

Examining mechanisms of protein complex at a basic cell biological level
News

Examining mechanisms of protein complex at a basic cell biological level

Feb. 1, 2025

Mary Munson is co-corresponding author on a study revealing functions and mechanisms of the exocyst that are essential to how molecules move across a membrane through vesicles in a cell.

Breaking through limits in kinase inhibition
Webinar

Breaking through limits in kinase inhibition

Jan. 31, 2025

Paul Shapiro, the first speaker on ASBMB Breakthroughs, a new webinar series highlighting research from ASBMB journals, discussed taking ideas and discoveries from basic science research toward clinical applications.

How opposing metabolic pathways regulate inflammation
Journal News

How opposing metabolic pathways regulate inflammation

Jan. 28, 2025

Researchers use cybernetics to understand what happens when two acids produced by macrophages compete for binding sites on the enzyme that converts them to active products.

We are all mosaics
News

We are all mosaics

Jan. 25, 2025

Your body is a collection of cells carrying thousands of genetic mistakes accrued over a lifetime — many harmless, some bad, and at least a few that may be good for you.